Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Current AMD laser therapies will dwindle in growing US ophthalmic surgical market

This article was originally published in Clinica

Executive Summary

The US market for energy-based ophthalmic surgical systems totalled nearly $1.7bn in 2013 and is expected to experience healthy, mid-single digit growth over the next half-decade. The use of these systems is predicted to increase in refractive surgery and the treatment of cataracts, glaucoma and diabetic retinopathy. But while the incidence of age-related macular degeneration (AMD) is expected to increase significantly, then number of laser-based procedures like retinal photocoagulation and photodynamic therapy this field will decline due to its limited effectiveness and the increasing end-user adoption of anti-VEGF therapy.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts